Viral Vector And Plasmid DNA Manufacturing Market | USD 40.71 Billion by 2034
The viral vector and plasmid DNA manufacturing market size was exhibited at USD 6.41 billion in 2024 and is projected to hit around USD 40.71 billion by 2034, growing at a CAGR of 20.3% during the forecast period 2025 to 2034.
The U.S. viral vector and plasmid DNA manufacturing market size is evaluated at USD 2.36 billion in 2024 and is projected to be worth around USD 14.96 billion by 2034, growing at a CAGR of 18.27% from 2025 to 2034.
North America dominated the market and accounted for 48.96% share in 2024. This can be attributed to the growing engagement of companies in research and product development in gene & cell therapy coupled with a substantial number of contract development organizations in the region. In addition, homegrown companies are expanding their manufacturing facilities in the region.The U.S. held the highest revenue share in North America viral vectors and plasmid DNA manufacturing market owing to the presence of key market players, including CDMOs offering GMP manufacturing services, and the adoption of highly innovative manufacturing technologies for production.
Asia Pacific is expected to be the fastest-growing region with a CAGR during the forecast period. China is one of the leading countries due to advancements in the regulatory framework for cell-based research activities in the country contributing to the Asia Pacific market growth. Increasing development and commercialization of novel vaccines in the China is also expected to contribute to market growth. For instance, in January 2021, Advaccine Biopharmaceuticals Suzhou Co., Ltd and INOVIO signed licensing agreement to commercialize INO-800—a COVID-19 DNA vaccine—in greater China area, including Taiwan, Hong Kong, Macao, and Mainland China.
The viral vectors and plasmid DNA manufacturing market in China is experiencing significant growth due to increased demand for gene therapies, advancements in biotechnology, and supportive government initiatives. The country's expanding biopharmaceutical sector, coupled with a large patient population, creates a robust market for the manufacturing of viral vectors and plasmid DNA, driving industry growth.
| Report Coverage | Details |
| Market Size in 2025 | USD 7.71 Billion |
| Market Size by 2034 | USD 40.71 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 20.3% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Vector Type, Workflow, Application, End-use, Disease, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Merck KGaA, Lonza; FUJIFILM Diosynth Biotechnologies; Thermo Fisher Scientific; Cobra Biologics; Catalent Inc.; Wuxi Biologics; TakarBio Inc.; Waisman Biomanufacturing; Genezen laboratories; Batavia Biosciences; Miltenyi Biotec GmbH; SIRION Biotech GmbH; Virovek Incorporation; BioNTech IMFS GmbH; Audentes Therapeutics; BioMarin Pharmaceutical; RegenxBio, Inc. |
Based on the vector type, the adeno-associated virus (AAV) segment led the market with a largest revenue share of 20% in 2024. AAVs are in huge demand and their utilization in clinical trials is increasing rapidly as these viruses offer maximum precision in delivering the gene to the region of interest. The increasing adoption is due to clinical trials relating to the development of orthopedic and ocular gene therapy therapies exhibiting increased efficiency and efficacy. In August 2022, an article published in Springer stated that AAV-mediated gene therapy could prevent acquired hearing loss. Application of AAV is rising significantly across various therapeutic areas, thereby witnessing a boost in its adoption rate.
The lentivirus segment is expected to grow at a significant CAGR over the forecast period. Increasing use of lentiviral vectors in ongoing research areas, the research industry is focusing on advancements in these vectors. For instance, scientists are studying the potential of non-integrating lentiviral vectors (NILVs) as a tool to avoid insertional mutagenesis. NILVs can transduce both non-dividing and dividing cells. These vectors have potential applications in CAR-T cell therapy research. Furthermore, a recent study published in June 2022 stated that lentiviral vectors are being used to develop vaccines that specifically target dendritic cells and stimulate a powerful T-cell immune response. These factors are expected to support market growth in the forecast years.
Based on the workflow, the downstream processing segment dominated the market in 2024 with a largest revenue share of 53.3%, owing to highly complex procedures carried out for polishing and purification of clinical grade final products. Increase in demand for clinical grade viral vectors, manufacturers are involved in development of novel economic downstream processes to address the challenges associated with conventional lab-scale manufacturing of vectors and is expected to support market growth. For example, combining a fed-batch fermentation technique and genetically optimized cell systems with conventional and novel technologies for the purification of vectors.
The upstream processing segment is expected to grow at significant CAGR over the forecast period. Upstream processing involves infecting cells with virus, cultivating of cells, and harvesting the virus from cells. Advanced product development, such as ambr 15 microbioreactor system for high-throughput upstream process development, is expected to drive the segment. ambr 15 microbioreactor system allows efficient cell culture processing with automated experimental set up and sampling, which requires less labor and laboratory space and time taken for cleaning and sterilization is also very less.
Based on the application, the vaccinology segment dominated the market in 2024 with a largest revenue share of 22.0%. The increasing demand for vaccines for various diseases, such as cancer and infectious diseases like COVID-19, primarily drives this growth. Viral vectors and plasmid DNA are widely used in the development of vaccines, and the increasing emphasis on research and development of new vaccines is expected to drive the growth of this market segment. In addition, the availability of government funding for vaccine development programs is also contributing to the growth of the vaccinology application in the viral vectors and plasmid DNA manufacturing market.
The cell therapy segment is expected to grow at the fastest CAGR over the forecast period owing to increase in personalized cancer treatments. Moreover, the success of Chimeric Antigen Receptor (CAR)-based cell therapies for cancer treatment is expected to further fuel the market growth.
Based on the end use, the research institutes segment dominated the market with the largest revenue share of 58.0% in 2024. Research activities carried out pertaining to improvement in vector production by research entities is driving the segment. For instance, in July 2021, Bluebird Bio and the Institute for NanoBiotechnology entered a research collaboration to develop novel technologies that boost the production of viral vectors for development of novel gene therapies. The researchers at Institute of NanoBiotechnology developed a highly effective and shelf-stable formulation of ready-to-dose form of DNA particles for producing viral vectors. Increasing number of such research collaborations are expected to fuel market growth.
The pharmaceutical and biotechnology companies segment is expected to grow significant CAGR over the forecast period. This can be attributed to continuous introduction of advanced therapies coupled with subsequent increase in the number of gene therapy-based research programs by pharmaceutical firms. The number of biotech companies that are employing vectors for therapeutics production continues to increase over time.
Based on the disease, the cancer segment dominated the market in 2024 with a largest revenue share of 38.0%. According to Globocan, the number of new cancer cases is anticipated to reach 28.4 million within the next two decades, with a rise of 47% from 2020, owing to adoption of western lifestyle, high consumption of alcohol, smoking, poor diet choices, and physical inactivity. Growing number of cancer cases is projected to propel the demand for gene therapies to treat cancer patients, consequently, increasing demand for viral vectors and plasmid DNA for the development of these gene therapies.
The genetic disorders are expected to register the significant CAGR during the forecast period. Genetic disorders are the most focused area of application for gene therapy, with more than 10% of ongoing clinical trials directed toward the same. This makes gene therapy for genetic disorders one of the most crucial markets in the forecast years and it expected to support growth of viral vectors and plasmid DNA manufacturing market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the viral vector and plasmid DNA manufacturing market
By Vector Type
By Workflow
By Application
By End-use
By Disease
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vector type
1.2.2. Workflow
1.2.3. Application
1.2.4. End-use
1.2.5. Disease
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
3.2.1.2. Technological Advancements in Manufacturing Vectors
3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
3.2.2. Market restraint analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis
4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
4.2. Adeno-associated virus (AAV)
4.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
4.3. Lentivirus
4.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
4.4. Adenovirus
4.4.1. Market estimates and forecasts 2021 to 2034, (USD Million)
4.5. Retrovirus
4.5.1. Market estimates and forecasts 2021 to 2034, (USD Million)
4.6. Plasmids
4.6.1. Market estimates and forecasts 2021 to 2034, (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts 2021 to 2034, (USD Million)
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis
5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
5.2. Upstream Manufacturing
5.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
5.2.2. Vector Amplification & Expansion
5.2.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
5.2.3. Vector Recovery/Harvesting
5.2.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
5.3. Downstream Manufacturing
5.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
5.3.2. Purification
5.3.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
5.3.3. Fill Finish diagnostic instruments
5.3.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
6.2. Gene Therapy
6.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
6.3. Cell Therapy
6.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
6.4. Vaccinology
6.4.1. Market estimates and forecasts 2021 to 2034, (USD Million)
6.5. Research Applications
6.5.1. Market estimates and forecasts 2021 to 2034, (USD Million)
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis
7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
7.2. Pharmaceutical and Biopharmaceutical Companies
7.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
7.3. Research Institutes
7.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
8.2. Cancer
8.2.1. Market estimates and forecasts 2021 to 2034, (USD Million)
8.3. Genetic Disorders
8.3.1. Market estimates and forecasts 2021 to 2034, (USD Million)
8.4. Infectious Diseases
8.4.1. Market estimates and forecasts 2021 to 2034, (USD Million)
8.5. Other
8.5.1. Market estimates and forecasts 2021 to 2034, (USD Million)
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2024 & 2034
9.2. North America
9.2.1. North America market estimates and forecasts 2021 to 2034, (USD Million)
9.2.2. U.S.
9.2.2.1. Key country dynamics
9.2.2.2. Regulatory framework
9.2.2.3. Competitive scenario
9.2.2.4. U.S. market estimates and forecasts 2021 to 2034, (USD Million)
9.2.2.5. Target disease prevalence
9.2.3. Canada
9.2.3.1. Key country dynamics
9.2.3.2. Regulatory framework
9.2.3.3. Competitive scenario
9.2.3.4. Canada market estimates and forecasts 2021 to 2034, (USD Million)
9.2.3.5. Target disease prevalence
9.3. Europe
9.3.1. Europe market estimates and forecasts 2021 to 2034, (USD Million)
9.3.2. UK
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. UK market estimates and forecasts 2021 to 2034, (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Germany
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Germany market estimates and forecasts 2021 to 2034, (USD Million)
9.3.3.5. Target disease prevalence
9.3.4. France
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework
9.3.4.3. Competitive scenario
9.3.4.4. France market estimates and forecasts 2021 to 2034, (USD Million)
9.3.4.5. Target disease prevalence
9.3.5. Italy
9.3.5.1. Key country dynamics
9.3.5.2. Regulatory framework
9.3.5.3. Competitive scenario
9.3.5.4. Italy market estimates and forecasts 2021 to 2034, (USD Million)
9.3.5.5. Target disease prevalence
9.3.6. Spain
9.3.6.1. Key country dynamics
9.3.6.2. Regulatory framework
9.3.6.3. Competitive scenario
9.3.6.4. Spain market estimates and forecasts 2021 to 2034, (USD Million)
9.3.6.5. Target disease prevalence
9.3.7. Norway
9.3.7.1. Key country dynamics
9.3.7.2. Regulatory framework
9.3.7.3. Competitive scenario
9.3.7.4. Norway market estimates and forecasts 2021 to 2034, (USD Million)
9.3.7.5. Target disease prevalence
9.3.8. Sweden
9.3.8.1. Key country dynamics
9.3.8.2. Regulatory framework
9.3.8.3. Competitive scenario
9.3.8.4. Sweden market estimates and forecasts 2021 to 2034, (USD Million)
9.3.8.5. Target disease prevalence
9.3.9. Denmark
9.3.9.1. Key country dynamics
9.3.9.2. Regulatory framework
9.3.9.3. Competitive scenario
9.3.9.4. Denmark market estimates and forecasts 2021 to 2034, (USD Million)
9.3.9.5. Target disease prevalence
9.4. Asia Pacific
9.4.1. Asia Pacific market estimates and forecasts 2021 to 2034, (USD Million)
9.4.2. Japan
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Japan market estimates and forecasts 2021 to 2034, (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. China
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. China market estimates and forecasts 2021 to 2034, (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. India
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. India market estimates and forecasts 2021 to 2034, (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Australia
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Australia market estimates and forecasts 2021 to 2034, (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. South Korea
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. South Korea market estimates and forecasts 2021 to 2034, (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Thailand
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Thailand market estimates and forecasts 2021 to 2034, (USD Million)
9.4.7.5. Target disease prevalence
9.5. Latin America
9.5.1. Latin America market estimates and forecasts 2021 to 2034, (USD Million)
9.5.2. Brazil
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Brazil market estimates and forecasts 2021 to 2034, (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. Mexico
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. Mexico market estimates and forecasts 2021 to 2034, (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Argentina
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Argentina market estimates and forecasts 2021 to 2034, (USD Million)
9.5.4.5. Target disease prevalence
9.6. MEA
9.6.1. MEA market estimates and forecasts 2021 to 2034, (USD Million)
9.6.2. South Africa
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. South Africa market estimates and forecasts 2021 to 2034, (USD Million)
9.6.2.5. Target disease prevalence
9.6.3. Saudi Arabia
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework
9.6.3.3. Competitive scenario
9.6.3.4. Saudi Arabia market estimates and forecasts 2021 to 2034, (USD Million)
9.6.3.5. Target disease prevalence
9.6.4. UAE
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework
9.6.4.3. Competitive scenario
9.6.4.4. UAE market estimates and forecasts 2021 to 2034, (USD Million)
9.6.4.5. Target disease prevalence
9.6.5. Kuwait
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework
9.6.5.3. Competitive scenario
9.6.5.4. Kuwait market estimates and forecasts 2021 to 2034, (USD Million)
9.6.5.5. Target disease prevalence
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2024
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Lonza
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. FUJIFILM Diosynth Biotechnologies
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Thermo Fisher Scientific
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Cobra Biologics
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Catalent Inc.
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Wuxi Biologics
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Takara Bio Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Waisman Biomanufacturing
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Genezen laboratories
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
10.4.11. Batavia Biosciences
10.4.11.1. Company overview
10.4.11.2. Financial performance
10.4.11.3. Product benchmarking
10.4.11.4. Strategic initiatives
10.4.12. Miltenyi Biotec GmbH
10.4.12.1. Company overview
10.4.12.2. Financial performance
10.4.12.3. Product benchmarking
10.4.12.4. Strategic initiatives
10.4.13. SIRION Biotech GmbH
10.4.13.1. Company overview
10.4.13.2. Financial performance
10.4.13.3. Product benchmarking
10.4.13.4. Strategic initiatives
10.4.14. Virovek Incorporation
10.4.14.1. Company overview
10.4.14.2. Financial performance
10.4.14.3. Product benchmarking
10.4.14.4. Strategic initiatives
10.4.15. BioNTech IMFS GmbH
10.4.15.1. Company overview
10.4.15.2. Financial performance
10.4.15.3. Product benchmarking
10.4.15.4. Strategic initiatives
10.4.16. Audentes Therapeutics
10.4.16.1. Company overview
10.4.16.2. Financial performance
10.4.16.3. Product benchmarking
10.4.16.4. Strategic initiatives
10.4.17. BioMarin Pharmaceutical
10.4.17.1. Company overview
10.4.17.2. Financial performance
10.4.17.3. Product benchmarking
10.4.17.4. Strategic initiatives
10.4.18. RegenxBio, Inc.
10.4.18.1. Company overview
10.4.18.2. Financial performance
10.4.18.3. Product benchmarking
10.4.18.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers